Investigating the safety and effectiveness of empagliflozin for patients on dialysis with end-stage kidney disease.
Safety, tolerability, and feasibility of empagliflozin therapy in dialysis-dependent ESKD
This study is looking at how safe and helpful a medication called empagliflozin is for people with end-stage kidney disease who are on dialysis, especially in terms of protecting their heart and reducing serious risks like heart failure.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Utah NIH-funded |
| Lab location | 1 site (Salt Lake City, United States) |
| Project ID | NIH-10890073 on NIH RePORTER |
What this research studies
This research focuses on evaluating the safety, tolerability, and feasibility of empagliflozin, a medication that may help reduce cardiovascular risks in patients with end-stage kidney disease (ESKD) who are on dialysis. The study aims to understand how this medication can impact heart health, particularly in reducing the risk of heart failure and sudden cardiac death, which are significant concerns for dialysis patients. Participants will be monitored for any side effects and overall health improvements while receiving this treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults with end-stage kidney disease who are currently undergoing dialysis treatment.
Not a fit: Patients who are not on dialysis or those with contraindications to empagliflozin may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved heart health and reduced mortality rates for patients with end-stage kidney disease on dialysis.
How similar studies have performed: Previous research has shown that SGLT2 inhibitors can significantly improve cardiovascular outcomes in patients with diabetes, suggesting potential benefits for similar populations.
Where this research is happening
Salt Lake City, United States
- University of Utah — Salt Lake City, United States (Active)
Researchers
- Principal investigator: Cho, Monique Eun Hee — University of Utah
- Study coordinator: Cho, Monique Eun Hee
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.